HealthUnited States7 sourcesNeutral

The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China

73% of participants achieved Q16W dosing interval; Furthermore, nearly 60% of the participants held the potential to extend the dosing interval to Q20W.

Appeal Democrat

via Appeal Democrat - Corroborated by 6 others

March 24, 2026 | 12:00 AM UTCUpdated 2h ago

Share Read original

Read the full article at Appeal Democrat →

Source Verification

Corroboration Score: 7

This story was independently reported by 7 sources. Click any source to read the original article.

Comments

0 comments

Be respectful and constructive.

Loading comments...

NMDP(SM) Advances Cell Therapy Research in Clinical Practice and Patient Outcomes at EBMT 2026

Biospace-14h ago-1 sources

The Phase 3 Registration STAR Study of Efdamrofusp Alfa (IBI302) Met its Primary Endpoint, Making it the First Self-developed Extended-interval Treatment for nAMD in China

Source Verification

Comments

Trump Pummeled By Critics For Asking If He Could Beat Elvis In A Fight

Live Updates: US-Israeli war against Iran rages on in fourth week

Related Articles

Police hunting for thugs who raided Mukono businessman

PMC clears proposal for Bharat Mandapam in Pune near airport

NMDP(SM) Advances Cell Therapy Research in Clinical Practice and Patient Outcomes at EBMT 2026